<code id='502A58A1A6'></code><style id='502A58A1A6'></style>
    • <acronym id='502A58A1A6'></acronym>
      <center id='502A58A1A6'><center id='502A58A1A6'><tfoot id='502A58A1A6'></tfoot></center><abbr id='502A58A1A6'><dir id='502A58A1A6'><tfoot id='502A58A1A6'></tfoot><noframes id='502A58A1A6'>

    • <optgroup id='502A58A1A6'><strike id='502A58A1A6'><sup id='502A58A1A6'></sup></strike><code id='502A58A1A6'></code></optgroup>
        1. <b id='502A58A1A6'><label id='502A58A1A6'><select id='502A58A1A6'><dt id='502A58A1A6'><span id='502A58A1A6'></span></dt></select></label></b><u id='502A58A1A6'></u>
          <i id='502A58A1A6'><strike id='502A58A1A6'><tt id='502A58A1A6'><pre id='502A58A1A6'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:entertainment    Page View:1237

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In